カテゴリー： GlobalInfoResearch, 世界, 医療/バイオ

世界のレニン&アンジオテンシン&装置（RAS）作用剤市場2023年：企業・地域・タイプ・用途別分析

◆英語タイトル：Global Renin-Angiotensin-System (RAS)-Acting Agent Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

GlobalInfoResearchが発行した調査報告書（GIR23AG11542）◆商品コード：GIR23AG11542
◆発行会社（リサーチ会社）：GlobalInfoResearch
◆発行日：2023年8月
◆ページ数：104
◆レポート形式：英語 / PDF
◆納品方法：Eメール（注文後2-3日）
◆調査対象地域：グローバル
◆産業分野：医薬品＆ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

GlobalInfoResearchの最新の調査によると、世界のレニン&アンジオテンシン&装置（RAS）作用剤の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界のレニン&アンジオテンシン&装置（RAS）作用剤市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、タイプ別、用途別に記載されています。

市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。

本レポートの主な目的は次のとおりです。
- 世界および主要国の市場機会の規模を決定するため
- レニン&アンジオテンシン&装置（RAS）作用剤の成長可能性を評価するため
- 各製品および最終用途市場の将来の成長を予測するため
- 市場に影響を与える競争要因を評価するため

レニン&アンジオテンシン&装置（RAS）作用剤市場はタイプと用途によって区分されます。2018年～2029年において、量と金額の観点からタイプ別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

タイプ別セグメント
・アンジオテンシン変換酵素阻害剤（ACEi）、アンジオテンシン受容体拮抗薬（ARB）

用途別セグメント
・高血圧、心不全、慢性腎臓病、その他

主要な市場プレーヤー
・Novartis AG、Pfizer, Inc.、AstraZeneca plc、Merck & Co., Inc.、Sanofi S.A.、Bristol-Myers Squibb Company、Daiichi Sankyo Company,Limited、Takeda Pharmaceutical Company Limited、Boehringer lngelheim GmbH、Johnson & Johnson

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、レニン&アンジオテンシン&装置（RAS）作用剤製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なレニン&アンジオテンシン&装置（RAS）作用剤メーカーの企業概要、2019年～2022年までのレニン&アンジオテンシン&装置（RAS）作用剤の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なレニン&アンジオテンシン&装置（RAS）作用剤メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別レニン&アンジオテンシン&装置（RAS）作用剤の販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までのレニン&アンジオテンシン&装置（RAS）作用剤のタイプ別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域でのレニン&アンジオテンシン&装置（RAS）作用剤市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、およびレニン&アンジオテンシン&装置（RAS）作用剤の産業チェーンを掲載しています。
・第14、15章では、レニン&アンジオテンシン&装置（RAS）作用剤の販売チャネル、販売業者、顧客、調査結果について説明します。

・市場概要
– レニン&アンジオテンシン&装置（RAS）作用剤の概要
– タイプ別分析（2018年vs2022年vs2029年）：アンジオテンシン変換酵素阻害剤（ACEi）、アンジオテンシン受容体拮抗薬（ARB）
– 用途別分析（2018年vs2022年vs2029年）：高血圧、心不全、慢性腎臓病、その他
– 世界のレニン&アンジオテンシン&装置（RAS）作用剤市場規模・予測
– 世界のレニン&アンジオテンシン&装置（RAS）作用剤生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Novartis AG、Pfizer, Inc.、AstraZeneca plc、Merck & Co., Inc.、Sanofi S.A.、Bristol-Myers Squibb Company、Daiichi Sankyo Company,Limited、Takeda Pharmaceutical Company Limited、Boehringer lngelheim GmbH、Johnson & Johnson
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・タイプ別分析2018年-2029年：アンジオテンシン変換酵素阻害剤（ACEi）、アンジオテンシン受容体拮抗薬（ARB）
・用途別分析2018年-2029年：高血圧、心不全、慢性腎臓病、その他
・レニン&アンジオテンシン&装置（RAS）作用剤の北米市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・レニン&アンジオテンシン&装置（RAS）作用剤のヨーロッパ市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・レニン&アンジオテンシン&装置（RAS）作用剤のアジア市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・レニン&アンジオテンシン&装置（RAS）作用剤の南米市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・レニン&アンジオテンシン&装置（RAS）作用剤の中東・アフリカ市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

❖ レポートの目次 ❖

1 Market Overview
1.1 Product Overview and Scope of Renin-Angiotensin-System (RAS)-Acting Agent
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Angiotensin Converting Enzyme Inhibitors (ACEi)
1.3.3 Angiotensin Receptor Blockers (ARBs)
1.4 Market Analysis by Application
1.4.1 Overview: Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hypertension
1.4.3 Heart Failure
1.4.4 Chronic Kidney Disease
1.4.5 Other
1.5 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size & Forecast
1.5.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity (2018-2029)
1.5.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Novartis AG
2.1.1 Novartis AG Details
2.1.2 Novartis AG Major Business
2.1.3 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
2.1.4 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Novartis AG Recent Developments/Updates
2.2 Pfizer, Inc.
2.2.1 Pfizer, Inc. Details
2.2.2 Pfizer, Inc. Major Business
2.2.3 Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
2.2.4 Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Pfizer, Inc. Recent Developments/Updates
2.3 AstraZeneca plc
2.3.1 AstraZeneca plc Details
2.3.2 AstraZeneca plc Major Business
2.3.3 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
2.3.4 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 AstraZeneca plc Recent Developments/Updates
2.4 Merck & Co., Inc.
2.4.1 Merck & Co., Inc. Details
2.4.2 Merck & Co., Inc. Major Business
2.4.3 Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
2.4.4 Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Merck & Co., Inc. Recent Developments/Updates
2.5 Sanofi S.A.
2.5.1 Sanofi S.A. Details
2.5.2 Sanofi S.A. Major Business
2.5.3 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
2.5.4 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Sanofi S.A. Recent Developments/Updates
2.6 Bristol-Myers Squibb Company
2.6.1 Bristol-Myers Squibb Company Details
2.6.2 Bristol-Myers Squibb Company Major Business
2.6.3 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
2.6.4 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Bristol-Myers Squibb Company Recent Developments/Updates
2.7 Daiichi Sankyo Company,Limited
2.7.1 Daiichi Sankyo Company,Limited Details
2.7.2 Daiichi Sankyo Company,Limited Major Business
2.7.3 Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
2.7.4 Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Daiichi Sankyo Company,Limited Recent Developments/Updates
2.8 Takeda Pharmaceutical Company Limited
2.8.1 Takeda Pharmaceutical Company Limited Details
2.8.2 Takeda Pharmaceutical Company Limited Major Business
2.8.3 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
2.8.4 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
2.9 Boehringer lngelheim GmbH
2.9.1 Boehringer lngelheim GmbH Details
2.9.2 Boehringer lngelheim GmbH Major Business
2.9.3 Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
2.9.4 Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Boehringer lngelheim GmbH Recent Developments/Updates
2.10 Johnson & Johnson
2.10.1 Johnson & Johnson Details
2.10.2 Johnson & Johnson Major Business
2.10.3 Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
2.10.4 Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Johnson & Johnson Recent Developments/Updates
3 Competitive Environment: Renin-Angiotensin-System (RAS)-Acting Agent by Manufacturer
3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Manufacturer (2018-2023)
3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Manufacturer (2018-2023)
3.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Renin-Angiotensin-System (RAS)-Acting Agent by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Renin-Angiotensin-System (RAS)-Acting Agent Manufacturer Market Share in 2022
3.4.2 Top 6 Renin-Angiotensin-System (RAS)-Acting Agent Manufacturer Market Share in 2022
3.5 Renin-Angiotensin-System (RAS)-Acting Agent Market: Overall Company Footprint Analysis
3.5.1 Renin-Angiotensin-System (RAS)-Acting Agent Market: Region Footprint
3.5.2 Renin-Angiotensin-System (RAS)-Acting Agent Market: Company Product Type Footprint
3.5.3 Renin-Angiotensin-System (RAS)-Acting Agent Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Region
4.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Region (2018-2029)
4.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Region (2018-2029)
4.1.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Region (2018-2029)
4.2 North America Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value (2018-2029)
4.3 Europe Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value (2018-2029)
4.4 Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value (2018-2029)
4.5 South America Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value (2018-2029)
4.6 Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2018-2029)
5.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Type (2018-2029)
5.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2018-2029)
6.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Application (2018-2029)
6.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Application (2018-2029)
7 North America
7.1 North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2018-2029)
7.2 North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2018-2029)
7.3 North America Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country
7.3.1 North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Country (2018-2029)
7.3.2 North America Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2018-2029)
8.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2018-2029)
8.3 Europe Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country
8.3.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Country (2018-2029)
8.3.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Region
9.3.1 Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2018-2029)
10.2 South America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2018-2029)
10.3 South America Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country
10.3.1 South America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Country (2018-2029)
10.3.2 South America Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country
11.3.1 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Renin-Angiotensin-System (RAS)-Acting Agent Market Drivers
12.2 Renin-Angiotensin-System (RAS)-Acting Agent Market Restraints
12.3 Renin-Angiotensin-System (RAS)-Acting Agent Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Renin-Angiotensin-System (RAS)-Acting Agent and Key Manufacturers
13.2 Manufacturing Costs Percentage of Renin-Angiotensin-System (RAS)-Acting Agent
13.3 Renin-Angiotensin-System (RAS)-Acting Agent Production Process
13.4 Renin-Angiotensin-System (RAS)-Acting Agent Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Renin-Angiotensin-System (RAS)-Acting Agent Typical Distributors
14.3 Renin-Angiotensin-System (RAS)-Acting Agent Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

List of Tables
Table 1. Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 4. Novartis AG Major Business
Table 5. Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
Table 6. Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Novartis AG Recent Developments/Updates
Table 8. Pfizer, Inc. Basic Information, Manufacturing Base and Competitors
Table 9. Pfizer, Inc. Major Business
Table 10. Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
Table 11. Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Pfizer, Inc. Recent Developments/Updates
Table 13. AstraZeneca plc Basic Information, Manufacturing Base and Competitors
Table 14. AstraZeneca plc Major Business
Table 15. AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
Table 16. AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. AstraZeneca plc Recent Developments/Updates
Table 18. Merck & Co., Inc. Basic Information, Manufacturing Base and Competitors
Table 19. Merck & Co., Inc. Major Business
Table 20. Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
Table 21. Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Merck & Co., Inc. Recent Developments/Updates
Table 23. Sanofi S.A. Basic Information, Manufacturing Base and Competitors
Table 24. Sanofi S.A. Major Business
Table 25. Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
Table 26. Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Sanofi S.A. Recent Developments/Updates
Table 28. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 29. Bristol-Myers Squibb Company Major Business
Table 30. Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
Table 31. Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Bristol-Myers Squibb Company Recent Developments/Updates
Table 33. Daiichi Sankyo Company,Limited Basic Information, Manufacturing Base and Competitors
Table 34. Daiichi Sankyo Company,Limited Major Business
Table 35. Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
Table 36. Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Daiichi Sankyo Company,Limited Recent Developments/Updates
Table 38. Takeda Pharmaceutical Company Limited Basic Information, Manufacturing Base and Competitors
Table 39. Takeda Pharmaceutical Company Limited Major Business
Table 40. Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
Table 41. Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Takeda Pharmaceutical Company Limited Recent Developments/Updates
Table 43. Boehringer lngelheim GmbH Basic Information, Manufacturing Base and Competitors
Table 44. Boehringer lngelheim GmbH Major Business
Table 45. Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
Table 46. Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Boehringer lngelheim GmbH Recent Developments/Updates
Table 48. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 49. Johnson & Johnson Major Business
Table 50. Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
Table 51. Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Johnson & Johnson Recent Developments/Updates
Table 53. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 54. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Manufacturer (2018-2023) & (USD Million)
Table 55. Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 56. Market Position of Manufacturers in Renin-Angiotensin-System (RAS)-Acting Agent, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 57. Head Office and Renin-Angiotensin-System (RAS)-Acting Agent Production Site of Key Manufacturer
Table 58. Renin-Angiotensin-System (RAS)-Acting Agent Market: Company Product Type Footprint
Table 59. Renin-Angiotensin-System (RAS)-Acting Agent Market: Company Product Application Footprint
Table 60. Renin-Angiotensin-System (RAS)-Acting Agent New Market Entrants and Barriers to Market Entry
Table 61. Renin-Angiotensin-System (RAS)-Acting Agent Mergers, Acquisition, Agreements, and Collaborations
Table 62. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Region (2018-2023) & (K Units)
Table 63. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Region (2024-2029) & (K Units)
Table 64. Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Region (2018-2023) & (USD Million)
Table 65. Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Region (2024-2029) & (USD Million)
Table 66. Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Region (2018-2023) & (US$/Unit)
Table 67. Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Region (2024-2029) & (US$/Unit)
Table 68. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2018-2023) & (K Units)
Table 69. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2024-2029) & (K Units)
Table 70. Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Type (2018-2023) & (USD Million)
Table 71. Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Type (2024-2029) & (USD Million)
Table 72. Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Type (2018-2023) & (US$/Unit)
Table 73. Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Type (2024-2029) & (US$/Unit)
Table 74. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2018-2023) & (K Units)
Table 75. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2024-2029) & (K Units)
Table 76. Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Application (2018-2023) & (USD Million)
Table 77. Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Application (2024-2029) & (USD Million)
Table 78. Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Application (2018-2023) & (US$/Unit)
Table 79. Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Application (2024-2029) & (US$/Unit)
Table 80. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2018-2023) & (K Units)
Table 81. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2024-2029) & (K Units)
Table 82. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2018-2023) & (K Units)
Table 83. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2024-2029) & (K Units)
Table 84. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Country (2018-2023) & (K Units)
Table 85. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Country (2024-2029) & (K Units)
Table 86. North America Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Country (2018-2023) & (USD Million)
Table 87. North America Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Country (2024-2029) & (USD Million)
Table 88. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2018-2023) & (K Units)
Table 89. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2024-2029) & (K Units)
Table 90. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2018-2023) & (K Units)
Table 91. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2024-2029) & (K Units)
Table 92. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Country (2018-2023) & (K Units)
Table 93. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Country (2024-2029) & (K Units)
Table 94. Europe Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Country (2018-2023) & (USD Million)
Table 95. Europe Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Country (2024-2029) & (USD Million)
Table 96. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2018-2023) & (K Units)
Table 97. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2024-2029) & (K Units)
Table 98. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2018-2023) & (K Units)
Table 99. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2024-2029) & (K Units)
Table 100. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Region (2018-2023) & (K Units)
Table 101. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Region (2024-2029) & (K Units)
Table 102. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Region (2018-2023) & (USD Million)
Table 103. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Region (2024-2029) & (USD Million)
Table 104. South America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2018-2023) & (K Units)
Table 105. South America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2024-2029) & (K Units)
Table 106. South America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2018-2023) & (K Units)
Table 107. South America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2024-2029) & (K Units)
Table 108. South America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Country (2018-2023) & (K Units)
Table 109. South America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Country (2024-2029) & (K Units)
Table 110. South America Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Country (2018-2023) & (USD Million)
Table 111. South America Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Country (2024-2029) & (USD Million)
Table 112. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2018-2023) & (K Units)
Table 113. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2024-2029) & (K Units)
Table 114. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2018-2023) & (K Units)
Table 115. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2024-2029) & (K Units)
Table 116. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Region (2018-2023) & (K Units)
Table 117. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Region (2024-2029) & (K Units)
Table 118. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Region (2018-2023) & (USD Million)
Table 119. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Region (2024-2029) & (USD Million)
Table 120. Renin-Angiotensin-System (RAS)-Acting Agent Raw Material
Table 121. Key Manufacturers of Renin-Angiotensin-System (RAS)-Acting Agent Raw Materials
Table 122. Renin-Angiotensin-System (RAS)-Acting Agent Typical Distributors
Table 123. Renin-Angiotensin-System (RAS)-Acting Agent Typical Customers
List of Figures
Figure 1. Renin-Angiotensin-System (RAS)-Acting Agent Picture
Figure 2. Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value Market Share by Type in 2022
Figure 4. Angiotensin Converting Enzyme Inhibitors (ACEi) Examples
Figure 5. Angiotensin Receptor Blockers (ARBs) Examples
Figure 6. Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value Market Share by Application in 2022
Figure 8. Hypertension Examples
Figure 9. Heart Failure Examples
Figure 10. Chronic Kidney Disease Examples
Figure 11. Other Examples
Figure 12. Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity (2018-2029) & (K Units)
Figure 15. Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price (2018-2029) & (US$/Unit)
Figure 16. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Renin-Angiotensin-System (RAS)-Acting Agent by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Renin-Angiotensin-System (RAS)-Acting Agent Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Renin-Angiotensin-System (RAS)-Acting Agent Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Type (2018-2029) & (US$/Unit)
Figure 31. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Application (2018-2029) & (US$/Unit)
Figure 34. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value Market Share by Region (2018-2029)
Figure 54. China Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Renin-Angiotensin-System (RAS)-Acting Agent Market Drivers
Figure 75. Renin-Angiotensin-System (RAS)-Acting Agent Market Restraints
Figure 76. Renin-Angiotensin-System (RAS)-Acting Agent Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Renin-Angiotensin-System (RAS)-Acting Agent in 2022
Figure 79. Manufacturing Process Analysis of Renin-Angiotensin-System (RAS)-Acting Agent
Figure 80. Renin-Angiotensin-System (RAS)-Acting Agent Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 世界のレニン&アンジオテンシン&装置（RAS）作用剤市場2023年：企業・地域・タイプ・用途別分析(Global Renin-Angiotensin-System (RAS)-Acting Agent Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 世界のRAS作用剤市場2023年：企業・地域・タイプ・用途別分析
  • 世界の末梢作用抗肥満薬市場2023年：企業・地域・タイプ・用途別分析
  • RAS作用薬の世界市場2023～2031：薬物クラス別
  • 世界の直動式圧力調整器市場2023年：企業・地域・タイプ・用途別分析
  • 世界のカプセル発泡剤市場2023年：企業・地域・タイプ・用途別分析

    • ◆H&Iグローバルリサーチのお客様（例）◆